Manufacturer of Controlled Substances, Notice of Application, Alltech Associates, Inc., 30327 [2012-12379]

Download as PDF 30327 Federal Register / Vol. 77, No. 99 / Tuesday, May 22, 2012 / Notices Dated: May 15, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Application, Alltech Associates, Inc. [FR Doc. 2012–12326 Filed 5–21–12; 8:45 am] BILLING CODE 4410–09–P Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 19, 2012, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice Of Application; Research Triangle Institute Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 12, 2012, Research Triangle Institute, Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Marihuana (7360) ......................... Cocaine (9041) ............................. I II srobinson on DSK4SPTVN1PROD with NOTICES The Institute will manufacture marihuana, and cocaine derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 23, 2012. Dated: May 15, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–12381 Filed 5–21–12; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 17:20 May 21, 2012 Jkt 226001 Drug Drug Schedule Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ N,N-Dimethylamphetamine (1480) 4-Methylaminorex (cis isomer) (1590). Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) 2,5-Dimethoxy-4-(n)propylthiophenethylamine (7348). Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 4-Bromo-2,5-dimethoxy-amphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5-dimethoxy-amphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 2,5-Dimethoxy-4ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (7405). 4-Methoxyamphetamine (7411) ... Alpha-methyltryptamine (7432) .... Bufotenine (7433) ......................... Diethyltryptamine (7434) .............. Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 5-Methoxy-N,Ndiisopropyltryptamine (7439). N-Ethyl-1-phenylcyclohexylamine (7455). 1-(1-Phenylcyclohexyl)pyrrolidine (7458). 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470). Dihydromorphine (9145) ............... Heroin (9200) ............................... Normorphine (9313) ..................... Methamphetamine (1105) ............ 1-phenylcyclohexylamine (7460) II Phencyclidine (7471). PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I Phenylacetone (8501) .................. 1piperidinocyclohexanecarbonitrile (8603). Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) VII. Ecgonine (9180) ........................... Meperidine intermediate-B (9233) Noroxymorphone (9668) VII. Schedule II II II II II II The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 23, 2012. Dated: May 15, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–12379 Filed 5–21–12; 8:45 am] BILLING CODE 4410–09–P I I DEPARTMENT OF LABOR I Approval of Information Collection Requirements; Comment Request I Office of Federal Contract Compliance Programs, Labor. ACTION: Notice. AGENCY: I I I I I I I I I I I I I I I I II II The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a pre-clearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA). 44 U.S.C. 3506(c)(2)(A). This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Office of Federal Contract Compliance Programs is soliciting comments on its SUMMARY: E:\FR\FM\22MYN1.SGM 22MYN1

Agencies

[Federal Register Volume 77, Number 99 (Tuesday, May 22, 2012)]
[Notices]
[Page 30327]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12379]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Application, 
Alltech Associates, Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 19, 2012, Alltech 
Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
N,N-Dimethylamphetamine (1480).............  I
4-Methylaminorex (cis isomer) (1590).......  I
Alpha-ethyltryptamine (7249)...............  I
Lysergic acid diethylamide (7315)..........  I
2,5-Dimethoxy-4-(n)-                         I
 propylthiophenethylamine (7348).
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
4-Bromo-2,5-dimethoxy-amphetamine (7391)...  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxy-amphetamine (7395)..  I
2,5-Dimethoxyamphetamine (7396)............  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
N-Hydroxy-3,4-methylenedioxyamphetamine      I
 (7402).
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
Alpha-methyltryptamine (7432)..............  I
Bufotenine (7433)..........................  I
Diethyltryptamine (7434)...................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).  I
N-Ethyl-1-phenylcyclohexylamine (7455).....  I
1-(1-Phenylcyclohexyl)pyrrolidine (7458)...  I
1-[1-(2-Thienyl)-cyclohexyl]piperidine       I
 (7470).
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Normorphine (9313).........................  I
Methamphetamine (1105).....................  II
1-phenylcyclohexylamine (7460) II            II
 Phencyclidine (7471).
Phenylacetone (8501).......................  II
1-piperidinocyclohexanecarbonitrile (8603).  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120) VII..................
Ecgonine (9180)............................  II
Meperidine intermediate-B (9233)...........  II
Noroxymorphone (9668) VII..................
------------------------------------------------------------------------

    The company plans to manufacture high purity drug standards used 
for analytical applications only in clinical, toxicological, and 
forensic laboratories.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than July 23, 2012.

     Dated: May 15, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-12379 Filed 5-21-12; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.